These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 6821364

  • 1. Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction and cytotoxic response.
    Schirrmacher V, Landolfo S, Zawatzky R, Kirchner H.
    Invasion Metastasis; 1981; 1(3):175-94. PubMed ID: 6821364
    [Abstract] [Full Text] [Related]

  • 2. Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. I. Effect of incompatibilities at H-2 or non-H-2 genes in normal and nude (nu/nu) mice.
    Schirrmacher V.
    Invasion Metastasis; 1981; 1(1):4-21. PubMed ID: 7188381
    [Abstract] [Full Text] [Related]

  • 3. H-41, a new minor histocompatibility locus. I. Histogenetic analysis.
    Juretić A, Vucak I, Malenica B, Nagy ZA, Klein J.
    J Immunol; 1984 Dec; 133(6):2950-4. PubMed ID: 6386980
    [Abstract] [Full Text] [Related]

  • 4. Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells.
    Altevogt P, Leidig S, Heckl-Oestreicher B.
    Cancer Res; 1984 Nov; 44(11):5305-13. PubMed ID: 6333273
    [Abstract] [Full Text] [Related]

  • 5. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming.
    Bevan MJ.
    J Immunol; 1976 Dec; 117(6):2233-8. PubMed ID: 825578
    [Abstract] [Full Text] [Related]

  • 6. Modulation of F1 cytotoxic potentials by GvHR: role and mode of action of non-MHC genes that determine the hybrid resistance to GvHR-associated suppression of F1 cytotoxic potential.
    Ishikawa H, Kubota E, Saito K.
    J Immunol; 1984 May; 132(5):2218-25. PubMed ID: 6232314
    [Abstract] [Full Text] [Related]

  • 7. CD4+ helper T cells are required for resistance to a highly metastatic murine tumor.
    Schild HJ, Kyewski B, Von Hoegen P, Schirrmacher V.
    Eur J Immunol; 1987 Dec; 17(12):1863-6. PubMed ID: 2961578
    [Abstract] [Full Text] [Related]

  • 8. H-2-linked genetic control of resistance to histocompatible tumors.
    Williams RM, Dorf ME, Benacerraf B.
    Cancer Res; 1975 Jun; 35(6):1586-90. PubMed ID: 805662
    [Abstract] [Full Text] [Related]

  • 9. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
    Müerköster S, Wachowski O, Zerban H, Schirrmacher V, Umansky V, Rocha M.
    Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
    [Abstract] [Full Text] [Related]

  • 10. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML, Parenza M, Parmiani G.
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [Abstract] [Full Text] [Related]

  • 11. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
    Kaido TJ, Maury C, Gresser I.
    Cancer Res; 1995 Dec 15; 55(24):6133-9. PubMed ID: 8521404
    [Abstract] [Full Text] [Related]

  • 12. Immune selection in murine tumors. Ph.d thesis.
    Svane IM, Engel AM.
    APMIS Suppl; 2003 Dec 15; (106):1-46. PubMed ID: 12739251
    [Abstract] [Full Text] [Related]

  • 13. Loss of endogenous mouse mammary tumor virus superantigen increases tumor resistance.
    Schirrmacher V, Beutner U, Bucur M, Umansky V, Rocha M, von Hoegen P.
    J Immunol; 1998 Jul 15; 161(2):563-70. PubMed ID: 9670928
    [Abstract] [Full Text] [Related]

  • 14. Reduced diversity of CTLs specific for multiple minor histocompatibility antigens relative to allograft rejection in vivo.
    Nevala WK, Paul C, Wettstein PJ.
    J Immunol; 1997 Feb 01; 158(3):1102-7. PubMed ID: 9013948
    [Abstract] [Full Text] [Related]

  • 15. Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites.
    Ksander BR, Streilein JW.
    J Immunol; 1989 Jul 15; 143(2):426-31. PubMed ID: 2500481
    [Abstract] [Full Text] [Related]

  • 16. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
    Zangemeister-Wittke U, Schirrmacher V.
    Biotherapy; 1991 Jul 15; 3(4):319-29. PubMed ID: 1786195
    [Abstract] [Full Text] [Related]

  • 17. Minor histocompatibility antigen-dependent rejection of Pam 212 epidermoid carcinoma by DBA/2 mice.
    Chen Z, Knepper JE, Gaspari AA.
    Cell Immunol; 1995 Aug 15; 164(1):90-9. PubMed ID: 7543374
    [Abstract] [Full Text] [Related]

  • 18. Carcinogenicity of tumor cell populations: origin of a putative H-2 isoantigenic loss variant tumor.
    Kerbel RS, Florian M, Man MS, Dennis J, McKenzie IF.
    J Natl Cancer Inst; 1980 May 15; 64(5):1221-30. PubMed ID: 6929020
    [Abstract] [Full Text] [Related]

  • 19. Chronic rejection of murine cardiac allografts discordant at the H13 minor histocompatibility antigen correlates with the generation of the H13-specific CD8+ cytotoxic T cells.
    Yang J, Jaramillo A, Liu W, Olack B, Yoshimura Y, Joyce S, Kaleem Z, Mohanakumar T.
    Transplantation; 2003 Jul 15; 76(1):84-91. PubMed ID: 12865791
    [Abstract] [Full Text] [Related]

  • 20. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
    Apasov SG, Sitkovsky MV.
    J Immunol; 1994 Mar 01; 152(5):2087-97. PubMed ID: 8133027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.